Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

157 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Thymoglobulin, CYA and mycophenolate mofetil as GVHD prophylaxis for reduced-intensity unrelated donor hematopoietic cell transplantation: beneficial effect seen on chronic GVHD.
Rodriguez R, Nademanee A, Palmer JM, Parker P, Nakamura R, Snyder D, Pullarkat V, Zain J, Smith E, Sahebi F, Patane K, Senitzer D, Chang K, Forman SJ. Rodriguez R, et al. Among authors: zain j. Bone Marrow Transplant. 2010 Jan;45(1):205-7. doi: 10.1038/bmt.2009.112. Epub 2009 Jun 8. Bone Marrow Transplant. 2010. PMID: 19503110 Clinical Trial. No abstract available.
Characteristics and Outcomes for Hospitalized Patients With Cutaneous T-Cell Lymphoma.
Glinos G, Wei G, Nosewicz J, Abdulla F, Chen PL, Chung C, Kaffenberger BH, Querfeld C, Shinohara MM, Sokol L, Zain J, Kumar A, Seminario-Vidal L. Glinos G, et al. Among authors: zain j. JAMA Dermatol. 2023 Feb 1;159(2):192-197. doi: 10.1001/jamadermatol.2022.5740. JAMA Dermatol. 2023. PMID: 36598766 Free PMC article.
A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphoma.
Merrill MH, Dahi PB, Redd RA, McDonough MM, Chen YB, DeFilipp Z, Herrera AF, Fisher DC, LaCasce AS, Odejide OO, Ng SY, Jacobson CA, Merryman RW, Kim AI, Nieto YL, Sauter CS, Shah GL, Zain JM, Armand P, Jacobsen ED. Merrill MH, et al. Blood. 2023 Aug 17;142(7):621-628. doi: 10.1182/blood.2023020244. Blood. 2023. PMID: 37319432 Free PMC article. Clinical Trial.
Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma.
Chavez JC, Foss FM, William BM, Brammer JE, Smith SM, Prica A, Zain JM, Tuscano JM, Shah H, Mehta-Shah N, Geethakumari PR, Wang BX, Zantinge S, Wang L, Zhang L, Boutrin A, Zhao W, Cheng L, Standifer N, Hewitt L, Enowtambong E, Shao W, Sharma S, Carlesso G, Moscow JA, Siu LL. Chavez JC, et al. Clin Cancer Res. 2023 May 15;29(10):1869-1878. doi: 10.1158/1078-0432.CCR-22-2955. Clin Cancer Res. 2023. PMID: 36826995 Free PMC article.
Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II-IV peripheral T-cell lymphoma.
Stuver R, Horwitz SM, Advani RH, Vose JM, Lee HJ, Mehta-Shah N, Zain JM, Haverkos B, Lechowicz MJ, Moskowitz AJ, Pham LQ, Leyden E, Ansell SM, Lunning MA. Stuver R, et al. Among authors: zain jm. Br J Haematol. 2023 Aug;202(3):525-529. doi: 10.1111/bjh.18885. Epub 2023 May 22. Br J Haematol. 2023. PMID: 37217196 Free PMC article. Clinical Trial.
Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies.
Han TH, Chen R, Advani R, Berryman RB, Smith SE, Forero-Torres A, Rosenblatt JD, Smith MR, Zain J, Hunder NN, Engert A. Han TH, et al. Among authors: zain j. Cancer Chemother Pharmacol. 2013 Jul;72(1):241-9. doi: 10.1007/s00280-013-2192-z. Epub 2013 May 30. Cancer Chemother Pharmacol. 2013. PMID: 23719719 Free PMC article. Clinical Trial.
157 results